Kyntra Bio vs Traws Pharma
KYNB and TRAW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KYNB and TRAW compare
Kyntra Bio is the larger company, worth 3.6 times as much as Traws Pharma ($13.9M against $3.9M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KYNB | TRAW |
|---|---|---|
| Size and price | ||
| Market cap | $13.9M | $3.9M |
| Share price | $3.44 | $0.251 |
| Change, 1 year | −62.3% | −88.3% |
| Change, 5 years | −98.9% | −99.7% |
| Beta (5Y) | 1.24 | 1.19 |
| Employees | 34 | 7 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 0.1× | – |
| P/S | 3.0× | – |
| FCF yield | −273% | – |
| Growth | ||
| Revenue growth (TTM) | −37.1% | – |
| Revenue growth, 5Y average | −48.4% | 64.6% (better) |
| Profitability | ||
| Gross margin | 6.3% | – |
| Operating margin | −1090% | – |
| Net margin | 3968% | – |
| FCF margin | −824% | – |
| Financial health | ||
| Interest coverage | −5.4× | – |
| Current ratio | 2.69 (better) | 0.93 |
| Altman Z-score | −24.47 (better) | −85.39 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −109% |
| Shareholder yield | 0.00% (better) | −109% |
| Ownership | ||
| Held by institutions | 24.7% | 40.1% |
| Held by insiders | 15.7% | 35.7% |
| Insider net buying, 12 months | $39.7K | $998K (better) |
| Short interest, % of float | 2.8% | 6.9% |
Go deeper
- KYNB stock overview
- KYNB income statement
- KYNB valuation and score
- TRAW stock overview
- TRAW income statement
- TRAW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.